Why the study?
Does TCV-116 (angiotensin AT1 receptor antagonist) reduce cardiac hypertrophy and altered gene expression in TGR(mRen2)27 transgenic rats compared to other antihypertensive combinations?
Does TCV-116 (angiotensin AT1 receptor antagonist) reduce cardiac hypertrophy and altered gene expression in TGR(mRen2)27 transgenic rats compared to other antihypertensive combinations?
In a transgenic rat model, angiotensin AT1 receptor antagonism regressed cardiac hypertrophy and remodeling more effectively than other antihypertensive agents with similar blood pressure-lowering effects, highlighting the role of the local renin-angiotensin system.
Hypothesis-generating for AT1-specific hypertrophy regression beyond BP control; leaves open translation to human therapy.
BACKGROUND: The transgenic rat TGR(mRen2)27, carrying the mouse Ren-2 gene, is a new model to elucidate the role of the local renin-angiotensin system in vivo. However, the role of the local renin-angiotensin system in the heart remains to be determined in TGR(mRen2)27. METHODS AND RESULTS: TGR(mRen2)27 were treated with various antihypertensive drugs for 6 weeks to examine the effects on cardiac hypertrophy and gene expression. Cardiac mRNAs were examined by Northern blot analysis. In TGR(mRen2)27, left ventricular hypertrophy was associated with a decrease in alpha-myosin heavy chain expression of 31% and an increase in skeletal alpha-actin and atrial natriuretic polypeptide expression by 2.6- and 21-fold, respectively (P < .05), thereby showing the shift of myocardium to a fetal phenotype. Furthermore, cardiac collagen and laminin expressions were increased in TGR(mRen2)27 (P < .05), suggesting the occurrence of cardiac remodeling. Although treatment of TGR(mRen2)27 with a high dose of TCV-116 (angiotensin AT1 receptor antagonist) or manidipine (calcium antagonist) combined with atenolol (beta 1-adrenergic receptor blocker) completely normalized blood pressure, TCV-116 regressed cardiac hypertrophy and suppressed the changes in cardiac mRNA levels of TGR(mRen2)27 much more potently than manidipine with atenolol. Furthermore, the inhibitory effects of a low dose of TCV-116 on cardiac hypertrophy and altered gene expressions of TGR(mRen2)27 were greater than those of doxazosin (alpha 1-adrenergic receptor blocker) combined with atenolol, despite their similar hypotensive effects. CONCLUSIONS: Our present observations provide evidence that the cardiac renin-angiotensin system in TGR(mRen2)27 is responsible for cardiac hypertrophy, phenotypic modulation, and remodeling.
No takes yet. Share an insight, caveat, or question.
Ohta et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: